Evolus Inc Stock Today
| EOLS Stock | USD 12.96 0.14 1.07% |
Performance0 of 100
| Odds Of DistressLess than 43
|
Evolus is selling for under 12.96 as of the 5th of December 2024; that is 1.07 percent decrease since the beginning of the trading day. The stock's lowest day price was 12.72. Evolus has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Evolus Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of December 2022 and ending today, the 5th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of February 2018 | Category Healthcare | Classification Health Care |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 63.32 M outstanding shares of which 5.29 M shares are currently shorted by private and institutional investors with about 8.04 trading days to cover. More on Evolus Inc
Moving against Evolus Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Evolus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | David Moatazedi |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
| Average Analyst Recommendation | |
Evolus Inc (EOLS) is traded on NASDAQ Exchange in USA. It is located in 520 Newport Center Drive, Newport Beach, CA, United States, 92660 and employs 322 people. Evolus is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 820.65 M. Evolus Inc conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 63.32 M outstanding shares of which 5.29 M shares are currently shorted by private and institutional investors with about 8.04 trading days to cover.
Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51.
Check Evolus Probability Of Bankruptcy
Ownership AllocationEvolus holds a total of 63.32 Million outstanding shares. The majority of Evolus Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Evolus Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Evolus. Please pay attention to any change in the institutional holdings of Evolus Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Evolus Ownership Details
Evolus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Soleus Capital Management, L.p. | 2024-09-30 | 1 M | |
| Millennium Management Llc | 2024-09-30 | 1 M | |
| Schroder Investment Management Group | 2024-09-30 | 1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1 M | |
| Lord, Abbett & Co Llc | 2024-09-30 | 995.4 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 983.7 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 970.3 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 955.6 K | |
| Rice Hall James & Associates, Llc | 2024-09-30 | 904.9 K | |
| Perceptive Advisors Llc | 2024-09-30 | 5.4 M | |
| Tang Capital Management Llc | 2024-09-30 | 4.8 M |
Evolus Inc Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Evolus market risk premium is the additional return an investor will receive from holding Evolus long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.28) |
Evolus Stock Against Markets
Evolus Corporate Management
| Jessica Novak | Senior Resources | Profile | |
| Tomoko YamagishiDressler | Chief Officer | Profile | |
| CCFP DipSportMed | Chief RD | Profile | |
| David Erickson | VP Relations | Profile |
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.